GLP-1 receptor agonists demonstrate emerging effects on addictive behaviors including cannabis use, which family medicine clinicians should recognize as a potential therapeutic benefit beyond glycemic and weight management in patients with comorbid substance use disorders. This mechanism appears related to dopaminergic pathway modulation and reward system alterations, adding clinical complexity to patient counseling regarding expected medication effects and potential behavioral changes during treatment. Understanding these effects enables better risk stratification and monitoring in patients with addiction histories who are candidates for GLP-1 therapy.
Recent observational data suggest that GLP-1 receptor agonists may influence substance use patterns, particularly regarding cannabis and other addictive substances. Several mechanisms have been proposed to explain these observations, including direct effects on dopaminergic reward pathways that GLP-1 signaling modulates, as well as indirect effects through weight loss and improved metabolic health that may reduce psychological drivers of substance use. Patients receiving GLP-1 therapy for weight management have reported decreased cravings and altered consumption patterns for cannabis, alcohol, and other substances in preliminary reports, suggesting that the neurobiological effects of GLP-1 receptor activation extend beyond glucose homeostasis and appetite regulation.
The clinical relevance of these observations for prescribing practitioners centers on the potential for GLP-1 agents to address comorbid addiction and metabolic disease simultaneously. Patients with obesity frequently have concurrent substance use disorders, and the metabolic benefits of GLP-1 therapy are well established. If these agents indeed reduce addictive behaviors through their effects on reward processing, they could provide an additional therapeutic benefit beyond glycemic control and weight loss. However, the current evidence base consists primarily of patient-reported outcomes and observational data rather than randomized controlled trials specifically designed to evaluate addiction endpoints.
For practitioners considering GLP-1 therapy in patients with known substance use disorders or addiction histories, these preliminary findings warrant discussion during informed consent conversations. The potential reduction in addiction-related behaviors could represent a meaningful benefit in the treatment of metabolic disease, while the mechanisms underlying these effects warrant further investigation through rigorous clinical study to establish causality and quantify the magnitude of benefit across different substance classes and patient populations.
GLP-1 receptor agonists may reduce addictive substance use behaviors, including cannabis consumption, through mechanisms affecting reward processing and impulse control in the brain. Preliminary evidence suggests these medications influence dopamine signaling pathways that underlie addiction vulnerability, though long-term clinical outcomes require further study. In family medicine practice, this potential benefit should not be positioned as a primary indication for GLP-1 therapy, but rather noted as an emerging secondary benefit worthy of patient discussion. When counseling patients with concurrent obesity and substance use disorder, document baseline substance use patterns and educate patients that any observed reduction in cravings may reflect the medication’s neurobiological effects rather than willpower alone.
“What we’re observing in clinical practice aligns with emerging data showing that GLP-1 receptor agonists appear to modulate reward-seeking behavior broadly, not just for food. The mechanism likely involves dopaminergic signaling in the ventral tegmental area, which explains why we’re seeing reported reductions in cannabis use, alcohol consumption, and other addictive behaviors alongside weight loss in our patient populations. This doesn’t mean GLP-1s are addiction treatments, but it does mean we need to counsel patients about potential changes in their substance use patterns and screen more carefully for behavioral shifts during treatment. The clinical implication here is straightforward: when a patient starts a GLP-1, I explicitly discuss that they may notice reduced cravings for things beyond food, and I monitor for any rapid changes in their relationship with alcohol or other substances, as sudden shifts in consumption can have medical consequences worth tracking.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Can GLP-1 drugs help me reduce my cannabis use?
Some patients report decreased cannabis use while taking GLP-1 medications, though this is not an FDA-approved use for these drugs. The mechanism appears related to how GLP-1s affect appetite and reward pathways in the brain, but more research is needed to understand this effect fully.
Will GLP-1 treatment cure my addiction?
GLP-1 drugs are not addiction treatments and should not replace evidence-based addiction care like counseling or medication-assisted treatment. If you struggle with substance use, talk to your doctor about comprehensive addiction services alongside any other treatments.
How do GLP-1 drugs affect the brain’s reward system?
GLP-1 medications activate receptors in brain areas involved in appetite and reward processing, which may reduce cravings for various substances including food and potentially other addictive behaviors. This is an active area of research but the exact mechanisms are still being studied.
Is it safe to use GLP-1 drugs if I have a history of substance abuse?
You should disclose your full medical history, including any substance use disorder, to your prescribing physician before starting GLP-1 therapy. Your doctor can assess whether GLP-1 is appropriate for you and monitor for any interactions with your specific situation.
Can GLP-1 drugs replace addiction counseling or support groups?
No, GLP-1 medications are not a substitute for evidence-based addiction treatment like therapy, counseling, or support programs. These medications may be used alongside traditional addiction care, but only under medical supervision.
Why might people use less cannabis on GLP-1 medication?
GLP-1 drugs may reduce cannabis use through multiple pathways including decreased overall reward-seeking behavior, changes in appetite regulation, and alterations in how the brain processes cravings. Researchers are studying whether this is a direct effect of the medication or related to other lifestyle changes patients experience.
Will GLP-1 help me quit smoking or drinking?
While some patients report reduced interest in various substances on GLP-1 therapy, these drugs are not approved for smoking or alcohol cessation. If you want to quit smoking or drinking, ask your doctor about proven treatments like nicotine replacement or FDA-approved medications for alcohol use disorder.
What should I tell my doctor about substance use before starting GLP-1?
You should inform your doctor about all current and past substance use, including alcohol, tobacco, cannabis, and any other drugs. This information helps your doctor determine if GLP-1 is safe for you and allows for appropriate monitoring during treatment.
Are there side effects when combining GLP-1 drugs with substance use?
Combining GLP-1 medications with active substance use could pose risks that haven’t been fully studied, so your doctor needs to know about any substance use before prescribing. Your healthcare provider can discuss specific interactions and safety concerns relevant to your situation.
Does GLP-1 therapy treat the underlying causes of addiction?
GLP-1 drugs may reduce certain addictive behaviors through neurological pathways, but they do not address underlying causes like trauma, mental health disorders, or social factors that drive addiction. Comprehensive addiction treatment requires addressing these root causes with appropriate mental health and behavioral support.
